Abraxane®

Description:

Abraxane® (paclitaxel protein-bound nanoparticles for injectable suspension)(albumin-bound) is an injectable suspension administered as a first-line treatment with carboplatin for non-small lung cancer (NSCLC) and as a second-line treatment for breast cancer. Abraxane® was FDA approved for breast cancer in 2005 and in 2012 for NSCLC.

Product Released: 
January, 2005
October, 2012
Information Verified: 
April, 2013

Californa Locations:

Displaying 1 - 1 of 1